Morbidity and prognosis after therapeutic lymph node dissections for malignant melanomaAlexander C. J. van Akkooi, Johannes H. W. de Wilt, Marna G. Bouwhuis et al.|European Journal of Surgical Oncology|2006Cited by 135
Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies—EORTC 18991Marna G. Bouwhuis, Alexander M.M. Eggermont, François Salès et al.|Journal of Clinical Oncology|2010Cited by 84
Autoimmune Antibodies and Recurrence-Free Interval in Melanoma Patients Treated With Adjuvant InterferonMarna G. Bouwhuis, Stefan Suciu, Sandra Collette et al.|JNCI Journal of the National Cancer Institute|2009Cited by 73
Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?Marna G. Bouwhuis, Rajiv Kumar, Andreas Gast et al.|Cancer Immunology Immunotherapy|2009Cited by 61
Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanomaAlexander C. J. van Akkooi, Alexander M.M. Eggermont, Marna G. Bouwhuis et al.|British journal of surgery|2007Cited by 60